Mylan Welcomes Teva's Decision - Quick Facts

(RTTNews) - Mylan N.V. (MYL) issued a statement regarding Teva's (TEVA) announcement of its entry into an agreement to acquire Allergan's Generic Drug Unit and its withdrawal of its unsolicited expression of interest to acquire Mylan. Mylan said its strategic focus remains unchanged.

"We congratulate Teva on their agreement to acquire Allergan's generics business and welcome their continued, and potentially enhanced, commitment to the generics industry."

Mylan Executive Chairman Robert Coury said: "Combining Mylan and Perrigo will create a unique infrastructure that is able to maximize on evolving industry dynamics and capitalize on key trends. We look forward to the next step in the process to make our combination with Perrigo a reality - the vote by Mylan shareholders to support this transaction - which we expect to occur in the next several weeks."